Welcome to our dedicated page for CALBF news (Ticker: CALBF), a resource for investors and traders seeking the latest updates and insights on CALBF stock.
Core One Labs Inc. (CALBF) is a biotechnology leader advancing psychedelic medicine through innovative research and patented production systems. This page aggregates official company announcements, regulatory developments, and scientific breakthroughs in psychedelic therapeutics.
Investors and researchers will find timely updates on psilocybin production innovations, clinical trial progress, and strategic partnerships. Our curated news feed includes press releases about intellectual property milestones, laboratory advancements, and compliance achievements within regulated frameworks.
Key content categories feature updates from subsidiaries Vocan Biotechnologies and Awakened Biosciences, covering engineered bacteria systems, pharmaceutical formulations, and neurological treatment research. Bookmark this page for verified information on CALBF's contributions to mental health therapeutics and biotech innovation.
Core One Labs has entered into a loan agreement with Right Season Investments, dated June 28, 2024. Under this agreement, Right Season has provided a CDN$300,000 loan to Core One. The loan carries an annual interest rate of 15% and is repayable on demand. Core One intends to use the funds for general administrative and working capital needs.
